NASDAQ · Biotechnology

GRCE (GRCE) Stock

$2.37 +3.04% NASDAQ: GRCE Healthcare

Valuation

MetricValue
Price$2.37
Market Cap$38.57M
P/E Ratio-2.26
P/B Ratio0.51
P/S Ratio0.00
EPS (TTM)$-0.95
52-Week High$5.18
52-Week Low$1.79
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-10.22%
ROA-10.84%
ROCE-35.82%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio11.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-26.0M$-19.0M$-71.0M$-17.0M$-24.0M
Net Profit$-31.0M$-12.0M$-57.0M$-17.0M$-14.0M
EPS$-12.59$-2.02$-7.72$-1.83$-1.13
Op Margin-8377.0%————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$78.0M$129.0M$79.0M$73.0M$72.0M
Total Liabilities$9.0M$20.0M$11.0M$12.0M$5.0M
Cash$64.0M$30.0M$28.0M$23.0M$22.0M
Borrowings$0$0$0$0$0

Latest News

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update GlobeNewswire · Jun 18, 2026 Sector Update: Health Care Stocks Edge Lower Late Afternoon MT Newswires · Apr 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-18.0M$-17.0M$-16.0M$-12.0M$-15.0M
Investing Cash Flow$-12.0M$-4.0M$13.0M$0$0
Financing Cash Flow$0$0$0$0$-1.0M
Net Cash Flow$46.0M$-21.0M$-2.0M$-5.0M$-1.0M
Free Cash Flow$-18.0M$-17.0M$-16.0M$-12.0M$-15.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-10.33
EV / EBITDA-1.37
FCF Yield-30.44%
Quick Ratio14.96
Interest Coverage—
Return 1Y-23.35%
Return 3Y-2.20%
Return 5Y-89.81%

Ownership

Insiders Held25.73%
Institutions Held26.46%
Institutions Float Held35.62%
Institutional HolderSharesReport Date
Cerity Partners LLC849,0552026-03-31
Eversept Partners, LP756,6002026-03-31
Nantahala Capital Management, LLC728,2032026-03-31
Bank of America Corporation494,7232026-03-31
Vanguard Capital Management LLC401,6562026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABVC $1.04 -3.70% -2.82 $15.07M 0.00%
ATNM $0.80 +1.32% -1.07 $25.02M 0.00%
CALCCalciMedica, Inc. $0.73 -3.82% -0.57 $11.55M 0.00%
LTRN $2.63 -0.75% -2.02 $33.56M 0.00%
LVTXLAVA Therapeutics N.V. $1.74 -3.87% -2.42 $45.77M 0.00%

About GRCE

GRCE is led by CEO Prashant Kohli, employs 4 people, headquartered in US, publicly traded since 2012.

GRCE stock trades at $2.37 with a market capitalization of $38.57M. The stock is valued at a price-to-earnings (P/E) ratio of -2.26, price-to-book of 0.51, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.79 and $5.18, and currently trades 54.2% below its 52-week high.

On profitability, GRCE generates a return on equity (ROE) of -10.22%, return on capital employed of -35.82%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides